Symbol not found

NASDAQ:NKTR   00:00AM GMT
0.00
0.00 (0.00%)
Earnings Announcements

Nektar Therapeutics Reports Second Quarter 2022 Financial Results

Published: 08/04/2022 21:27 GMT
Nektar Therapeutics (NKTR) - Reports Second Quarter 2022 Financial Results.
Revenue, Which Primarily Includes Non-cash Royalty Revenue, in Q2 of 2022 Was $21.6 Million.
Qtrly Loss per Share $0.85.
Q2 Earnings per Share View $-0.94, Revenue View $22.7 Million -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $22.65 Million
Adjusted EPS is expected to be -$0.44

Next Quarter Revenue Guidance is expected to be $22.46 Million
Next Quarter EPS Guidance is expected to be -$0.35

More details on our Analysts Page.